Answers are grounded in this paper and cite their sources.
T cell depletion by polyclonal antithymocyte globulins (ATG) has been used for many years in both organ and hematopoietic cell transplantation as an induction and rejection therapy. Nevertheless, its use remains largely empirical and many clinical questions, such as the determination of an individualized dose, therapeutic relevance of nondepletive effects, or prediction of long-term effects, are still unresolved. This review evaluates the evidence-based knowledge and the uncertainties concerning ATG, and suggests perspectives and opportunities for modern use of this old drug.
No takes yet. Share an insight, caveat, or question.
Bamoulid et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: